CG Oncology, Inc.

CGON

US1569441009

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-28 pm EDT			5-day change	1st Jan Change
31.57 ^USD	+4.36%		+0.45%	0.00%

Jun. 28	Sector Update: Health Care Stocks Decline in Late Afternoon Trading	MT
Jun. 28	Sector Update: Health Care Stocks Edge Higher in Afternoon Trading	MT

CG Oncology, Inc.(NasdaqGS:CGON) added to S&P Global BMI Index

June 23, 2024

Latest news about CG Oncology, Inc.

Sector Update: Health Care Stocks Decline in Late Afternoon Trading	Jun. 28	MT
Sector Update: Health Care Stocks Edge Higher in Afternoon Trading	Jun. 28	MT
Sector Update: Health Care	Jun. 28	MT
CG Oncology Bladder Cancer Treatment to Achieve $4 Billion in Sales by 2037, BofA Says	Jun. 28	MT
BofA Securities Initiates CG Oncology at Buy Rating With $65 Price Target	Jun. 28	MT
CG Oncology, Inc.(NasdaqGS:CGON) added to S&P Global BMI Index	Jun. 23	CI
CG Oncology, Inc.(NasdaqGS:CGON) added to S&P Biotechnology Select Industry Index	Jun. 23	CI
CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC	Jun. 06	CI
Sector Update: Health Care Stocks Softer in Friday Afternoon Trading	May. 24	MT
CG Oncology Shares Jump After Potential Combination Therapy for Bladder Cancer Meets Phase 2 Primary Endpoint	May. 24	MT
CG Oncology Says Potential Combination Therapy for Bladder Cancer Meets Phase 2 Primary Endpoint	May. 24	MT
CG Oncology, Inc. to Present Positive Final Results from Phase 2 Core-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC At Asco 2024 Annual Meeting	May. 24	CI
Goldman Sachs Upgrades CG Oncology to Buy From Neutral With $50 Price Target	May. 14	MT
CG Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
CG Oncology, Inc. Announces Data from the Phase 3 BOND-003 Study Evaluating the Efficacy and Safety of Cretostimogene Monotherapy in Patients with High-Risk Non-Muscle Invasive Bladder Cancer Unresponsive to Bacillus Calmette Guerin	May. 03	CI
PACS Group to raise $450 mln in US IPO at over $3 bln valuation	Apr. 10	RE
CG Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26	CI
CG Oncology, Inc.(NasdaqGS:CGON) added to S&P TMI Index	Mar. 17	CI
Cantor Fitzgerald Starts Coverage on CG Oncology With Overweight Rating, $75 Price Target	Feb. 20	MT
Goldman Sachs Initiates Coverage on CG Oncology With Neutral Rating, $42 Price Target	Feb. 20	MT
Morgan Stanley Initiates CG Oncology With Overweight Rating, Price Target is $55	Feb. 20	MT
HC Wainwright Starts Coverage on CG Oncology With Buy Rating, $75 Price Target	Feb. 14	MT
Moderna, Bayer-backed Metagenomi stock drops 32% on Nasdaq debut	Feb. 09	RE
Fractyl Health valued at $654.6 mln in tepid debut	Feb. 02	RE
Fractyl Health prices US IPO below range to raise $110 mln	Feb. 01	RE

CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The Companyâs product candidate, cretostimogene is initially in clinical development for the treatment of patients with non-muscle invasive bladder cancer (NMIBC). Its lead candidate, BOND-003 is a targeted oncolytic intravesically delivered immunotherapy agent that is in Phase II for the treatment of Bacillus Calmette Guerin (BCG) unresponsive and intermediate risk NMIBC disease. Its other product candidate CORE-001 is a Phase II single-arm, open-label clinical trial of cretostimogene administered with BCG-unresponsive NMIBC. Its portfolio also includes PIVOT-006, a Phase III trial to assess the safety and efficacy of adjuvant cretostimogene when administered as monotherapy to patients with intermediate-risk NMIBC following transurethral resection of the bladder tumor (TURBT).

Sector

Biotechnology & Medical Research

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

31.57 USD

Average target price

67.67 USD

Spread / Average Target

+114.34%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CG ONCOLOGY, INC.	0.00%	2.1B
MODERNA, INC.	+19.41%	45.51B
LONZA GROUP AG	+38.65%	39.36B
IQVIA HOLDINGS INC.	-8.62%	38.52B
ALNYLAM PHARMACEUTICALS, INC.	+26.95%	30.74B
CELLTRION, INC.	-13.50%	26.03B
ICON PUBLIC LIMITED COMPANY	+10.74%	25.92B
UNITED THERAPEUTICS CORPORATION	+44.87%	14.13B
MEDPACE HOLDINGS, INC.	+34.36%	12.73B
BIO-TECHNE CORPORATION	-7.14%	11.29B

Other Biotechnology & Medical Research

CG Oncology, Inc.

Equities

CGON

US1569441009

Biotechnology & Medical Research

CG Oncology, Inc.(NasdaqGS:CGON) added to S&P Global BMI Index

Latest news about CG Oncology, Inc.

Chart CG Oncology, Inc.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research